Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis

References

• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2016 (updated January 2016). Available from: http://www.goldcopd.org/Accessed April 7, 2016
   Google Scholar
• VosTFlaxmanADNaghaviMYears lived with disability (YLDs) for 1,160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592163219623245607
   PubMed Web of Science ®Google Scholar
• DavisRMNovotnyTEThe epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary diseaseAm Rev Respir Dis19891403 Pt 2S82S842782765
   PubMed Web of Science ®Google Scholar
• KojimaSSakakibaraHMotaniSIncidence of chronic obstructive pulmonary disease, and the relationship between age and smoking in a Japanese populationJ Epidemiol2007172546017420613
   PubMed Web of Science ®Google Scholar
• SchikowskiTSugiriDRanftULong-term air pollution exposure and living close to busy roads are associated with COPD in womenRespir Res2005615216372913
   PubMed Web of Science ®Google Scholar
• WHOChronic obstructive pulmonary disease (COPD)2016 Available from: http://www.who.int/mediacentre/factsheets/fs315/en/Accessed April 4, 2016
   Google Scholar
• CeledonJCLangeCRabyBAThe transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD)Hum Mol Genet200413151649165615175276
   PubMed Web of Science ®Google Scholar
• KeatingsVMCaveSJHenryMJA polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPDChest2000118497197511035665
   PubMed Web of Science ®Google Scholar
• AnzuetoASethiSMartinezFJExacerbations of chronic obstructive pulmonary diseaseProc Am Thorac Soc20074755456417878469
   PubMedGoogle Scholar
• Lopez-CamposJLTanWSorianoJBGlobal burden of COPDRespirology2016214142326494423
   PubMed Web of Science ®Google Scholar
• WHOHousehold air pollution and health, Fact sheet #2922016 Available from: http://www.who.int/mediacentre/factsheets/fs292/en/Accessed April 4, 2016
   Google Scholar
• NIH-NHLBMorbidity & mortality: 2012 chart book on cardiovascular, lung, and blood diseases2012 Available from: http://www.nhlbi.nih.gov/resources/docs/2012_ChartBook_508.pdfAccessed April 7, 2016
   Google Scholar
• FDA Drug Safety Communication: new safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs)2010 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776.htmAccessed September 27, 2016
   Google Scholar
• CazzolaMPageCLong-acting bronchodilators in COPD: where are we now and where are we going?Breathe2014102110120
   Google Scholar
• DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSINLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• KornSKerwinEAtisSAmosCOwenRLassenCINSIST study groupIndacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week studyRespir Med2011105571972621367594
   PubMed Web of Science ®Google Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat(R) in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled studyChest2014145598199124385182
   PubMed Web of Science ®Google Scholar
• MaltaisFSinghSDonaldACEffects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trialsTher Adv Respir Dis20148616918125452426
   PubMed Web of Science ®Google Scholar
• CopeSDonohueJFJansenJPComparative efficacy of long-acting bronchodilators for COPD: a network meta-analysisRespir Res20131410024093477
   PubMed Web of Science ®Google Scholar
• RoskellNSAnzuetoAHamiltonADisseBBeckerKOnce-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterolInt J Chron Obstruct Pulmon Dis2014981382425114521
   PubMed Web of Science ®Google Scholar
• AgustiAde TeresaLDe BackerWA comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPDEur Respir J201443376377224114969
   PubMed Web of Science ®Google Scholar
• CopeSCapkun-NiggliGGaleRJardimJRJansenJPComparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease–a network meta-analysisInt J Chron Obstruct Pulm Dis20116329344
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMMergelVLeselbaumARCaractaCFAUGMENT COPD study investigatorsEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• YaoWWangCZhongNEffect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific studyRespirology201419223123824383720
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• RossiAKristufekPLevineBEFormoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study GroupComparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPDChest200212141058106911948033
   PubMed Web of Science ®Google Scholar
• GrossNJNelsonHSLapidusRJEfficacy and safety of formoterol fumarate delivered by nebulization to COPD patientsRespir Med2008102218919718363201
   PubMed Web of Science ®Google Scholar
• KinoshitaMLeeSHHangLWEfficacy and safety of indacaterol 150 and 300 microg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled studyRespirology201217237938922122202
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLotvallJOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• GotfriedMHKerwinEMLawrenceDLassenCKramerBEfficacy of indacaterol 75 mug once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studiesCOPD20129662963623020650
   PubMedGoogle Scholar
• KerwinEMGotfriedMHLawrenceDLassenCKramerBEfficacy and tolerability of indacaterol 75 mug once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studiesClin Ther201133121974198422177371
   PubMed Web of Science ®Google Scholar
• FeldmanGSilerTPrasadNEfficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyBMC Pulm Med2010101120211002
   PubMed Web of Science ®Google Scholar
• StockleyRAChopraNRiceLAddition of salmeterol to existing treatment in patients with COPD: a 12 month studyThorax200661212212816443706
   PubMed Web of Science ®Google Scholar
• ChapmanKRArvidssonPChuchalinAGThe addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary diseaseCan Respir J20029317818512068339
   PubMedGoogle Scholar
• Rutten-van MolkenMRoosBVan NoordJAAn empirical comparison of the St George’s Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial settingThorax19995411995100310525558
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• JonesPWAndersonJACalverleyPMHealth status in the TORCH study of COPD: treatment efficacy and other determinants of changeRespir Res2011127121627828
   PubMed Web of Science ®Google Scholar
• CelliBHalpinDHepburnRByrneNKeatingETGoldmanMSymptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS)Respir Med200397Suppl AS35S43
   Google Scholar
• HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest2003124383484312970006
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200216681084109112379552
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax200358539940412728159
   PubMed Web of Science ®Google Scholar
• DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest20021221475512114338
   PubMed Web of Science ®Google Scholar
• JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
   PubMed Web of Science ®Google Scholar
• CopeSCapkun-NiggliGGaleREfficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparisonValue Health201215352453322583463
   PubMed Web of Science ®Google Scholar
• DonohueJFSystematic review comparing LABA, olodaterol, and indacaterol: limitationsInt J Chron Obstruct Pulmon Dis201491331133325525350
   PubMed Web of Science ®Google Scholar
• DahlRGreefhorstLANowakDInhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200116477878411549532
   PubMed Web of Science ®Google Scholar